Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
محتوای ارائه شده توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Player FM - برنامه پادکست
با برنامه Player FM !
با برنامه Player FM !
Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy
Manage episode 302410929 series 2857008
محتوای ارائه شده توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Go online to PeerView.com/WNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the treatment landscape for gastric and gastroesophageal junction (GEJ) cancers continues to evolve, patients with these heterogenous and aggressive malignancies are benefiting from improved outcomes. Targeted therapies, such as anti-angiogenic agents, have had a beneficial role in the second-line gastric and GEJ cancer settings after prior fluoropyrimidine- or platinum-containing chemotherapy, while novel combinations with anti-angiogenesis agents, chemotherapy, and/or immunotherapy are showing promise in clinical trials. Furthermore, first-line therapy with an immune checkpoint inhibitor in combination with chemotherapy recently demonstrated improved outcomes over chemotherapy alone, and these data led to an FDA approval that is ushering in a new immunotherapy-based standard of care in the frontline treatment of newly diagnosed gastric and GEJ cancers. Join PeerView for an innovative, case-based activity designed to bring participants the latest data on established targeted therapies and emerging combination strategies for patients with gastric and GEJ cancers and expert guidance on incorporating treatment advances into day-to-day clinical practice. With a focus on multidisciplinary care of patients with gastric and GEJ cancers, the faculty panel will address selection and sequencing of treatment regimens along with symptom management, psychological support, nutritional considerations, and a variety of other issues that affect patients’ quality of life and outcomes. Upon completion of this accredited CE activity, participants should be better able to: Evaluate the latest clinical evidence on established targeted therapies (eg, anti-angiogenic agents) and emerging combination strategies (eg, with chemotherapy or immune checkpoint inhibitors) for patients with advanced gastric or GEJ cancer, Discuss the clinical implications of recently approved and emerging first-line treatment strategies in the settings of advanced gastric or GEJ cancer that take into consideration the potential impact of treatment selection and sequencing beyond first-line therapy, Implement a tailored approach to treatment selection and sequencing over multiple lines of therapy, based on the latest clinical evidence, current practice guidelines, and patient-, disease-, and treatment-specific factors, for patients with advanced gastric or GEJ cancer, Integrate multidisciplinary, interprofessional, and holistic care strategies that address nutritional needs, emotional and psychological concerns, treatment-related adverse events, the risk of disease progression, and other issues into the management of patients with advanced gastric or GEJ cancer.
…
continue reading
532 قسمت
Manage episode 302410929 series 2857008
محتوای ارائه شده توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Go online to PeerView.com/WNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the treatment landscape for gastric and gastroesophageal junction (GEJ) cancers continues to evolve, patients with these heterogenous and aggressive malignancies are benefiting from improved outcomes. Targeted therapies, such as anti-angiogenic agents, have had a beneficial role in the second-line gastric and GEJ cancer settings after prior fluoropyrimidine- or platinum-containing chemotherapy, while novel combinations with anti-angiogenesis agents, chemotherapy, and/or immunotherapy are showing promise in clinical trials. Furthermore, first-line therapy with an immune checkpoint inhibitor in combination with chemotherapy recently demonstrated improved outcomes over chemotherapy alone, and these data led to an FDA approval that is ushering in a new immunotherapy-based standard of care in the frontline treatment of newly diagnosed gastric and GEJ cancers. Join PeerView for an innovative, case-based activity designed to bring participants the latest data on established targeted therapies and emerging combination strategies for patients with gastric and GEJ cancers and expert guidance on incorporating treatment advances into day-to-day clinical practice. With a focus on multidisciplinary care of patients with gastric and GEJ cancers, the faculty panel will address selection and sequencing of treatment regimens along with symptom management, psychological support, nutritional considerations, and a variety of other issues that affect patients’ quality of life and outcomes. Upon completion of this accredited CE activity, participants should be better able to: Evaluate the latest clinical evidence on established targeted therapies (eg, anti-angiogenic agents) and emerging combination strategies (eg, with chemotherapy or immune checkpoint inhibitors) for patients with advanced gastric or GEJ cancer, Discuss the clinical implications of recently approved and emerging first-line treatment strategies in the settings of advanced gastric or GEJ cancer that take into consideration the potential impact of treatment selection and sequencing beyond first-line therapy, Implement a tailored approach to treatment selection and sequencing over multiple lines of therapy, based on the latest clinical evidence, current practice guidelines, and patient-, disease-, and treatment-specific factors, for patients with advanced gastric or GEJ cancer, Integrate multidisciplinary, interprofessional, and holistic care strategies that address nutritional needs, emotional and psychological concerns, treatment-related adverse events, the risk of disease progression, and other issues into the management of patients with advanced gastric or GEJ cancer.
…
continue reading
532 قسمت
كل الحلقات
×به Player FM خوش آمدید!
Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.